Skip to content

EV / EBITDA at other companies

CVS Health logo
CVS HealthCVS
9.2×+2.7×
Privia Health Group, Inc. logo
Privia Health Group, Inc.PRVA
44.7×-33.3×
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
19×+3.3×
Surgery Partners, Inc. logo
Surgery Partners, Inc.SGRY
11.2×-4.4×
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
13.3×-4.0×
Alignment Healthcare logo
Alignment HealthcareALHC
48.5×

Other financials

Income statement

See full
Revenue$965.1M+55.6%
Gross profit$105.7M+48.2%
Operating income$28.5M+38.6%
Net income$14.4M+116%
EPS (diluted)$0.29+107%

Balance sheet

See full
Cash & equivalents$478.4M+85.0%
Total debt$1.1B+136%
Total equity$800.3M+7.4%
Total assets$2.4B+77.2%

Cash flow

See full
Operating cash flow$68.1M+309%
CapEx$4.0M+30.3%
Free cash flow$64.1M+372%

Valuation

See full
Market cap$2.04B-3.0%
Enterprise value$2.63B+22.0%
P/E67.6×
P/S0.6×-0.4×

Profitability

See full
Gross margin10.7%-1.3pp
Operating margin2.5%-1.1pp
Net margin0.9%
FCF margin4.6%

Returns & leverage

See full
Return on equity3.9%
Debt / equity1.3×+0.7×
Current ratio1.3×-0.4×

Where this comes from

Calculated from Astrana Health’s reported figures.

Based on the most recent quarter.

The official record: Astrana Health’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Astrana Health's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Astrana Health's EV / EBITDA?
Astrana Health (ASTH) reported EV / EBITDA of 13.8× in Q1 2026.
How has Astrana Health's EV / EBITDA changed year-over-year?
Astrana Health's EV / EBITDA decreased by 5.2% year-over-year, from 14.6× to 13.8×.
What is the long-term trend for Astrana Health's EV / EBITDA?
Over 5 years (2020 to 2025), Astrana Health's EV / EBITDA has grown at a 15.5% compound annual growth rate (CAGR), from 7.4× to 15.2×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.